All eyes are on the preliminary data Moderna is preparing to submit to the monitoring board on its vaccine candidate's effectiveness, which works on technology similar to Pfizer's.
The candidate is a so-called messenger RNA vaccine, based on technology similar to that used by one of the fastest-moving vaccine developers, Moderna Inc.
Moderna decided to make the declaration because investors had started noticing that the company has patents that might apply to other Covid vaccines, says its president.
The vaccine, called mRNA-1273, is being developed by Moderna with the US govt's National Institutes of Health. The small study involved 40 adults aged over 56.
The results from Moderna’s early-stage trial, which include data from 20 participants, are important because older adults often don’t respond as well to vaccines as younger adults.
While bond yields tend to fall amid low inflation & interest rate cuts, market experts say they’ve been rising due to concerns over tax collections, fiscal deficit & potential impact of US tariffs.
It is one of the most advanced long-range air defence and anti-missile radars. It has been acquired under an about USD 145-million deal signed in 2020.
In its toughest time in decades because of floods, Punjab would’ve expected PM Modi to visit. If he has the time for a Bihar tour, why not a short visit to next-door Punjab?
COMMENTS